CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net income	$ 158,178	$ 186,250
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	24,546	19,109
Non-cash compensation expense	151,920	97,473
Non-cash interest expense	10,871	11,315
Losses on Extinguishment of Debt	10,787	0
Other non-cash charges and expenses, net	6,598	18,323
Deferred taxes	(32,543)	92,522
Changes in assets and liabilites
Decrease (increase) in Sanofi, Bayer HealthCare, and trade accounts receivable	61,043	(206,149)
Increase in Inventories	(37,295)	(31,144)
(Increase) decrease in prepaid expenses and other assets	(29,446)	2,700
Increase (decrease) in deferred revenue	39,838	(11,579)
Increase in accounts payable, accrued expenses and other liabilities	16,820	35,592
Total adjustments	223,139	28,162
Net cash provided by operating activities	381,317	214,412
Cash flows from investing activities:
Purchases of marketable securities	(374,509)	(282,643)
Sales or maturities of marketable securities	155,850	307,244
Capital expenditures	(135,695)	(55,656)
Net cash used in investing activities	(354,354)	(31,055)
Cash flows from financing activities:
Payments in connection with facility and capital lease obligations	(534)	(997)
Repayments of convertible senior notes	(61,125)	0
Payments in connection with deduction of outstanding warrants	(143,041)	0
Proceeds from issuance of Common Stock	63,057	34,300
Payments in connection with Common Stock tendered for employee tax obligations	(64,990)	(73,137)
Excess tax benefit from stock-based compensation	244,197	7,876
Net cash provided by (used in) financing activities	37,564	(31,958)
Net increase in cash and cash equivalents	64,527	151,399
Cash and cash equivalents at beginning of period	535,608	230,276
Cash and cash equivalents at end of period	$ 600,135	$ 381,675